All In MedTech

Device Trial Radar · NCT06620237

BIO|MASTER.CSP Study

Pivotal Study of the Amvia Pacemaker and Solia CSP S Pacing Lead on Conduction System Pacing

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Oct 4, 2024

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Biotronik SE & Co. KGNot on our public-company list
Sponsor type
Industry
First posted
Oct 1, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to test the clinical safety and performance of the Amvia pacemakers and the Solia CSP S lead when used for left bundle branch area pacing (LBBAP). The patient population consist of patients with cardiac pacemaker indication or cardiac resynchronization therapy indication and intended for implantation of a system with left bundle branch area stimulation. Participants will visit sites at enrollment in the study, at implantation and pre-hospital discharge, 1-, 6- and 12-month follow-up visits. Additional annual follow-up(s) may apply until study termination after regulatory approval of Solia CSP S. The total duration of the clinical investigation is expected to be until September 2027, with last patient out (LPO). During the visits the regular pacemaker and lead measurement are performed. A 12-lead ECG is recorded to document intrinsic and ventricularly paced heart rhythm to assess left bundle branch area pacing. Programming of the pacemakers will be done according to the participant´s therapeutical needs. The study will be conducted in approximately 18 sites in Europe, Australia and New Zealand where more than one physician per site are expected to participate.

Conditions

  • Cardiac Pacing, Artificial
  • Cardiac Pacemaker, Artificial
  • Cardiac Resynchronization Therapy Devices
  • Bradycardia
  • Conduction Disorder
  • Conduction Defect, Cardiac
  • Heart Failure

Interventions

  • Implantation of the Solia CSP S pacing lead for LBBAPDevice

    Left bundle branch area pacing using a Solia CSP S lead

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amvia related SADE-d free rateTime frame: 6 months (183 days) after implantation
  2. Solia CSP S related SADE-d free rateTime frame: 6 months (183 days) after implantation

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Integral Healthcare

    Adelaide, Australia

  • Victorian Heart Hospital

    Clayton, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, Australia

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.